Monthly Patient Volumes of Buprenorphine-Waivered Clinicians in the US

Published in: JAMA Network Open, Volume 3, Issue 8 (2020). doi: doi.org/10.1001/jamanetworkopen.2020.14045

Posted on RAND.org on August 27, 2020

by Alexandra Duncan, Jared Anderman, Travis Deseran, Ian Reynolds, Bradley D. Stein

Read More

Access further information on this document at JAMA Network Open

This article was published outside of RAND. The full text of the article can be found at the link above.

Buprenorphine, which is effective in treating opioid use disorder (OUD), can be prescribed for OUD by clinicians who obtain a US Drug Enforcement Administration (DEA) X-license after completing a Substance Abuse and Mental Health Services Administration (SAMHSA)-approved training. Federal regulations currently limit these waivered clinicians to treating 30, 100, or 275 patients with buprenorphine concurrently, with clinicians able to request an increased amount if they are limited to treating 30 or 100 patients. Clinicians historically treat fewer patients with buprenorphine than their limit allows. Given efforts to increase buprenorphine use, this cross-sectional study examines the number of patients treated by waivered clinicians.

Research conducted by

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/principles.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.